Enterprise Associates 13 L. New Sells 1,784,109 Shares of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Stock
Enterprise Associates 13 L. New Sells 1,784,109 Shares of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Stock
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) major shareholder Enterprise Associates 13 L. New sold 1,784,109 shares of the firm's stock in a transaction dated Tuesday, October 25th. The stock was sold at an average price of $0.15, for a total transaction of $267,616.35. Following the completion of the sale, the insider now owns 4,857,525 shares of the company's stock, valued at $728,628.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
納斯達克(代碼：PHAS-GET評級)大股東Enterprise Associates 13 L.New在一項日期為10月25日(星期二)的交易中出售了該公司股票1,784,109股。該股以0.15美元的平均價格出售，總成交金額為267,616.35美元。出售完成後，這位內部人士現在擁有該公司4,857,525股股票，價值728,628.75美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。持有公司10%以上股份的大股東必須披露他們在美國證券交易委員會上的銷售和購買情況。
PhaseBio Pharmaceuticals Stock Performance
PhaseBio製藥類股表現
Shares of NASDAQ PHAS opened at $0.13 on Friday. The company has a market capitalization of $6.57 million, a price-to-earnings ratio of -0.06 and a beta of 2.87. The company has a 50 day simple moving average of $0.68 and a two-hundred day simple moving average of $0.87. PhaseBio Pharmaceuticals, Inc. has a fifty-two week low of $0.12 and a fifty-two week high of $4.08.
上週五，納斯達克PHA的股價開盤報0.13美元。該公司市值為657萬美元，市盈率為-0.06倍，貝塔係數為2.87。該公司的50日簡單移動均線切入位在0.68美元，200日簡單移動均線切入位在0.87美元。PhaseBio PharmPharmticals，Inc.的股價為0.12美元，為52周低點，52周高點為4.08美元。
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) last announced its quarterly earnings results on Friday, August 12th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $2.50 million.
PhaseBio製藥公司(納斯達克代碼：PHAS-GET Rating)最近一次公佈季度收益是在8月12日星期五。該公司公佈本季度每股收益(0.34美元)，低於普遍預期的(0.33美元)和(0.01美元)。該公司本季度營收為21萬美元，而市場普遍預期為250萬美元。
Institutional Investors Weigh In On PhaseBio Pharmaceuticals
機構投資者看好PhaseBio製藥公司
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several analysts have commented on PHAS shares. Cowen lowered shares of PhaseBio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday. Cowen downgraded shares of PhaseBio Pharmaceuticals to a "market perform" rating in a research note on Monday. Stifel Nicolaus downgraded shares of PhaseBio Pharmaceuticals from a "buy" rating to a "hold" rating and decreased their target price for the company from $15.00 to $1.00 in a research note on Wednesday, September 28th. Needham & Company LLC downgraded shares of PhaseBio Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, September 28th. Finally, William Blair downgraded shares of PhaseBio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Wednesday, September 28th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $4.50.
幾位分析師對PHAS的股票發表了評論。考恩在週一的一份報告中將PhaseBio製藥公司的股票評級從“跑贏大盤”下調至“市場表現”。考恩在週一的一份研究報告中將PhaseBio製藥公司的股票評級下調至“市場表現”。Stifel Nicolaus在9月28日週三的一份研究報告中將PhaseBio PharmPharmticals的股票評級從買入下調至持有，並將該公司的目標價從15.00美元下調至1.00美元。Needham&Company LLC在9月28日星期三的一份研究報告中將PhaseBio製藥公司的股票評級從“買入”下調至“持有”。最後，在9月28日星期三的一份研究報告中，威廉·布萊爾將PhaseBio製藥公司的股票評級從“跑贏大盤”下調至“市場表現”。根據MarketBeat的數據，五位股票研究分析師對該股的評級為持有，該公司目前的平均評級為“持有”，共識目標價為4.50美元。
PhaseBio Pharmaceuticals Company Profile
PhaseBio製藥公司簡介
(Get Rating)
(獲取評級)
PhaseBio Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension.
PhaseBio製藥公司是一家臨牀階段的生物製藥公司，致力於心血管疾病新療法的開發和商業化。該公司正在籌備中的藥物包括：用於抗血小板治療替卡格雷的新型逆轉藥bentracimab(PB2452)，用於治療肺動脈高壓的每週一次的血管活性腸肽受體激動劑pemziviptadil(PB1046)，以及用於治療頑固性高血壓的口服藥物PB6440。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on PhaseBio Pharmaceuticals (PHAS)
- Zim Integrated Shipping Services Stock: High Yield or High Risk?
- Can Mid-Cap Lantheus Continue its 2022 Outperformance?
- The One Question that Matters for Altria Stock
- The Institutions Box Up Dividend Growth with These Cheap Stocks
- Be Sure You Own United Parcel Service for the Right Reasons
- 免費獲取StockNews.com關於PhaseBio製藥(PHAs)的研究報告
- ZIM綜合航運服務股票：高收益還是高風險？
- 中型股蘭修斯能否繼續其2022年的優異表現？
- 對奧馳亞股票至關重要的一個問題
- 這些機構用這些廉價股票限制股息增長
- 確保您擁有聯合包裹服務公司的理由是正確的
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得PhaseBio製藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對PhaseBio製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。